A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 115-123

  Adjei, Alex A ^a   Dy, Grace K ^a   Erlichman, Charles ^a   Reid, Joel M ^a   Sloan, Jeff A ^a   Pitot, Henry C ^a   Alberts, Steven R ^a   Goldberg, Richard M ^a   Hanson, Lorelei J ^a   Atherton, Pamela J ^a   Watanabe, Tanya ^b   Geary, Richard S ^b   Holmlund, Jon ^b   Dorr, F Andrew ^b  

^a MAYO CLINIC   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GEMCITABINE; ISIS 2503;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GENE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; ONCOGENE H RAS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; RAS PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 12244260756     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hall, A. The cellular functions of small GRP-binding proteins. Science (Wash. DC), 249: 635-640, 1990.
2. Barbacid, M. Ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
3. Bos, J. L. Ras oncogenes in human cancer: a review [published erratum appears in Cancer Res., 50: 1352, 1990]. Cancer Res, 49: 4682-4689, 1989.
4. Willumsen, B. M. The ras Transforming Protein. Copenhagen: Academic Press, 1992.
5. Nagai, M. A., Habr-Gama, A., Oshima, C. T., and Brentani, M. M. Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors: frequency and clinical significance. Dis. Colon Rectum, 35: 444-451, 1992.
6. Hayashi, Y., Widjono, Y. W., Ohta, K., Hanioka, K., Obayashi, C., Itoh, K., Imai, Y., and Itoh, H. Expression of EGF, EGF-receptor, p53, v-erb b, and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. Pathol. Int., 44: 124-130, 1994.
7. Sun, X. F., Ekberg, H., Zhang, H., Carstensen, J. M., and Nordenskjold, B. Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma. APMIS, 106: 657-674, 1998.
8. Miyahara, M., Saito, T., Kaketani, K., Sato, K., Kuwahara, A., Shimoda, K., and Kobayashi, M. Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer. Dis. Colon Rectum, 34: 1097-1102, 1991.
9. Friess, H., Berberat, P., Schilling, M., Kunz, J., Korc, M., and Buchler, M. W. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J. Mol. Med., 74: 35-42, 1996.
10. Rusch, V., Baselga, J., Cordon-Cardo, C., Orazem, J., Zaman, M., Hoda, S., McIntosh, J., Kurie, J., and Dmitrovsky, E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res., 53 (Suppl. 10): 2379-2385, 1993.
11. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
12. Harpole, D. H., Jr., Marks, J. R., Richards, W. G., Herndon, J. E., and Sugarbaker, D. J. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin. Cancer Res., 1: 659-664, 1995.
13. Crooke, S. T. Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev., 6: 145-147, 1996.
14. Monia, B. P., Johnston, D. J., Ecker, D. J., Zounes, M. A., Lima, W. F., and Freier, S. M, Selective inhibition of mutant H-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem., 267: 19954-19962, 1992.
15. Monia, B. P. Disruption of the MAP kinase signaling pathway using antisense oligonucleotide inhibitors targeted to ras and raf kinase. In: C. A. Stein and A. M. Krieg (eds.), Applied Antisense Oligonucleotide Technology, pp. 245-261. New York: John Wiley and Sons, 1998.
16. Chen, G., Oh, S., Monia, B. P., and Stacey, D. W. Antisense oligonucleotides demonstrate a dominant role of c-Ki-ras proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem., 271: 28259-28265, 1996.
17. Dorr, A., Bruce, J., Monia, B., Johnston, J., Geary, R., Kwoh, T. J., Holmlund, J., and Nemunaitis, J. Phase I and pharmacokinetic trial of ISIS 2503, a 20-Mer antisense oligonucleotide against H-ras, by 14-day continuous infusion (CIV) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 18: A603, 1999.
18. Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D. K., and Levin, A. A. Antisense oligonucleotide inhibitors for the treatment of cancer: pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des., 12: 383-393, 1997.
19. Einhorn, L. H. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group Study. Semin. Oncol., 24 (Suppl. 8): 24-26, 1997.
20. Crino, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., Paccagnella, A., Adamo, V., Altavilla, G., Incoronato, P., Trippetti, M., Mosconi, A. M., Santucci, A., Sorbolini, S., Oliva, C., and Tonato, M. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a Phase II study. J. Clin. Oncol., 15: 297-303, 1997.
21. Sandler, A., Nemunaitis, J., Denham, C., Cormier, Y., von Pawel, J., Niyikiza, C., Nguyen, B., and Einhorn, L. Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 17: 454a, 1998.
22. Crino, L., Conte, P., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Matano, E., Mnarangolo, M., Bartolucci, R., Oliva, C., and Tonato, M. A randomized trial of gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC): a multicenter Phase III study. Proc. Am. Soc. Clin. Oncol., 17: 455a, 1998.
23. Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
24. Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., and Kaufmann, S. H. Synergy of the protein farnesyl transferase inhibitor SCH 66336 and cisplatin in human cancer cell lines. Clin. Cancer Res., 7: 1438-1445, 2001.
25. Leeds, J. M., Graham, M. J., Troung, L., and Cummins, L. L. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem., 235: 36-43, 1996.
26. Gibaldi, M., and Perrier, D. Pharmacokinetics, 2nd ed. New York: Dekker, Inc., 1982.
27. Cunningham, C. C., Holmlund, J. T., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A., and Nemunaitis, J. A Phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res., 6: 1626-1631, 2000.
28. Nemunaitis, J., Holmlund, J. T., Kraynak, M., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Geary, R., Dorr, A., Von Hoff, D., and Eckhardt, S. G. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer. J. Clin. Oncol., 17: 3586-3595, 1999.